# Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

> **NCT02752828** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 521 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine/lixisenatide (HOE901/AVE0010)
- **DRUG:** Insulin glargine (HOE901)
- **DRUG:** Oral anti-diabetic drugs

## Key facts

- **NCT ID:** NCT02752828
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-23
- **Primary completion:** 2018-03-12
- **Final completion:** 2018-03-12
- **Target enrollment:** 521 (ACTUAL)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752828, "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02752828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*